These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 15721412)
1. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412 [TBL] [Abstract][Full Text] [Related]
2. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054 [TBL] [Abstract][Full Text] [Related]
3. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. May T; Virtanen C; Sharma M; Milea A; Begley H; Rosen B; Murphy KJ; Brown TJ; Shaw PA Gynecol Oncol; 2010 Apr; 117(1):9-17. PubMed ID: 20117829 [TBL] [Abstract][Full Text] [Related]
4. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Tung CS; Mok SC; Tsang YT; Zu Z; Song H; Liu J; Deavers MT; Malpica A; Wolf JK; Lu KH; Gershenson DM; Wong KK Mod Pathol; 2009 Sep; 22(9):1243-50. PubMed ID: 19525924 [TBL] [Abstract][Full Text] [Related]
5. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184 [TBL] [Abstract][Full Text] [Related]
6. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Wamunyokoli FW; Bonome T; Lee JY; Feltmate CM; Welch WR; Radonovich M; Pise-Masison C; Brady J; Hao K; Berkowitz RS; Mok S; Birrer MJ Clin Cancer Res; 2006 Feb; 12(3 Pt 1):690-700. PubMed ID: 16467078 [TBL] [Abstract][Full Text] [Related]
18. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738 [TBL] [Abstract][Full Text] [Related]
19. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Chien J; Fan JB; Bell DA; April C; Klotzle B; Ota T; Lingle WL; Gonzalez Bosquet J; Shridhar V; Hartmann LC Gynecol Oncol; 2009 Jul; 114(1):3-11. PubMed ID: 19410283 [TBL] [Abstract][Full Text] [Related]
20. Gene microarray analysis of lncRNA and mRNA expression profiles in patients with high‑grade ovarian serous cancer. Lou Y; Jiang H; Cui Z; Wang X; Wang L; Han Y Int J Mol Med; 2018 Jul; 42(1):91-104. PubMed ID: 29577163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]